Major Companies in the South Korea ADHD Medication Market | Competitive Landscape 2026

South Korea ADHD Medication Market Overview

According to 6Wresearch, the South Korea ADHD Medication Market is poised for significant expansion, driven by a rapidly aging society and an increasing prevalence of metabolic syndromes. The rising cases of adult ADHD and paediatric diagnoses are boosting the demand for a diverse range of pharmacological interventions. Furthermore, improved healthcare infrastructure, along with consumer awareness about nerve health is strengthening the innovation of advanced therapies, including non-invasive nerve stimulation and next-generation pain management solutions.

Competitive Landscape

The competitive landscape of the South Korea ADHD medication industry is defined by continuous investment in biotechnology and strategic global partnerships. Leading brands are focused on innovating novel drug delivery systems and biologics. The market is highly competitive as key players strive to offer a comprehensive portfolio that spans from nerve supplements to advanced prescription-grade anaesthetics.

Below is a list of leading players operating in the South Korea ADHD Medication Market:

1. Janssen Korea

Janssen Korea is a dominant leader in the ADHD space, providing Concerta, which is essential for treating ADHD in paediatric and adult patients.

2. Whanin Pharm

Whanin Pharm is a local powerhouse known for its R&D in central nervous system therapies, offering high-quality methylphenidate formulations.

3. Myungin Pharm

Myungin Pharm contributes to the market with a robust portfolio of neuroprotective agents and specialized generic medications.

4. Takeda Korea

Takeda Korea maintains a strong presence with its specialized CNS portfolio, focusing on the introduction of long-acting stimulant treatments.

5. Medice (Distributed by various)

The Medice brand focuses on innovative biological treatments and supportive over-the-counter nerve health solutions that cater to the growing student population.

6. Handok

Handok is a leader in CNS research, developing next-generation therapies through strategic alliances with global innovators for neurological and behavioural health.

7. Boryung (formerly Boryung Pharmaceutical)

Boryung contributes to the market with its established portfolio of metabolic and CNS medications, managing the underlying comorbidities often associated with ADHD.

8. Chong Kun Dang

Chong Kun Dang is highly specialized in neurology, providing localized pharmacological solutions and R&D for neuro-psychiatric treatment advancement.

9. Dong-A ST

Dong-A ST provides specialized treatments for underlying neurological pathways and continues to invest in pharmaceutical innovation for the domestic mental health sector.